New hope for brain cancer: triple therapy targets deadliest tumor
NCT ID NCT03405792
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (temozolomide chemotherapy and Tumor Treating Fields) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 40 adults with this aggressive brain tumor will receive the triple combination. The goal is to see if this approach improves outcomes compared to past patients who received only standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florida Health
Gainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?